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Stroke ranks as the second most common cause of death and the commonest cause of disability worldwide.1,2 
Hypertension is the leading risk factor for both ischemic and 
hemorrhagic stroke (intracerebral hemorrhage [ICH])3,4 and 
accounts for half of the population attributable risk world-
wide.3,4 Blood pressure lowering lies at the core of primary 
and secondary stroke prevention strategies.5,6 We recently 
showed that high genetically predicted systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) are associ-
ated with all major ischemic stroke subtypes (large artery, 
cardioembolic, small vessel stroke), as well as with deep, but 
not lobar ICH.7 While these results support a causal associ-
ation of elevated blood pressure with the main stroke sub-
types, it remains unclear how these associations vary across 
the lifespan,8,9 given the hemodynamic changes that take 
place as a result of aging.10
With older age the large arteries become stiffer, thus lead-
ing to an increase in blood pressure pulsatility (pulse pressure 
[PP]), defined as the difference between SBP and DBP.10 This 
is associated with a greater transmission of pulsatile flow into 
the distal circulation and can lead to damage of end-organ vas-
cular beds including the cerebral circulation.11,12 Indeed, in ob-
servational studies, higher PP has been associated with risk of 
cardiovascular disease, including stroke, beyond mean arterial 
pressure (MAP).13–17 However, observational studies assess 
only a limited period of the natural history of cardiovascular 
disease, thus making it difficult to disentangle the dynamic 
interactions between MAP and PP and their associations with 
cardiovascular disease. For example, while increasing PP 
might accelerate vascular pathologies, the reverse might also 
be true, as, for example, atherosclerotic plaques lead to local 
arterial stiffening and higher PP.18 Furthermore, there are no 
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studies that sytematically explored the effects of MAP and PP 
across different age strata on stroke risk and how effects vary 
between etiologically defined stroke subtypes. Given the dif-
ferential efficacy of different antihypertensive drug classes for 
lowering MAP and PP,19,20 it is important to determine these 
associations to optimize blood pressure lowering approaches 
for stroke prevention.
By using genetic variants randomly allocated at concep-
tion as instrumental variables for traits of interest, Mendelian 
randomization (MR) overcomes key limitations of obser-
vational studies, assesses lifelong exposures to risk factors, 
and can clarify potential causal associations.21 By drawing 
on genome-wide association studies (GWAS) with detailed 
phenotyping of stroke cases, MR further enables the explo-
ration of etiological stroke subtypes. Here, we leveraged data 
from large-scale GWASs and the UK Biobank (UKB) and 
performed MR analyses to explore the independent effects of 
genetically predicted MAP and PP across different age strata 
on risk of ischemic stroke, ICH, and their main etiological 
subtypes in subjects aged 38 to 71 years.
Methods
Access to Data and Ethical Approval
The analyses for this study were based on publicly available sum-
mary statistics. The original studies have received institutional review 
board approval as appropriate. Data from the UKB can be accessed 
upon submission of a research proposal (application 2532 for the cur-
rent project). The summary data for the current analysis are available 
in the main article and in the Data Supplement. This MR study was 
performed in accordance with the STROBE-MR criteria.22 All statis-
tical analyses were undertaken using R (v3.5.0; The R Foundation for 
Statistical Computing).
GWASs for Age-Stratified Blood Pressure Traits in 
UKB
Data sources are detailed in Table 1. We performed GWAS for MAP 
and PP in the UKB population after stratifying the sample to indi-
viduals ≤55 and >55 years of age. We used the mean SBP and DBP 
from the 2 brachial measurements (automated or manual) performed 
at the baseline assessment and added 15 and 10 mm Hg to these 
values, respectively for individuals under treatment with antihyper-
tensive agents.23 PP was calculated as (SBP−DBP), whereas MAP 
was calculated as (DBP+[1/3]×PP). In the pooled sample, mean MAP 
and PP were 103.2 (SD: 11.9) mm Hg and 56.7 (SD: 13.6) mm Hg, 
respectively. We selected a threshold of 55 years of age, because this 
is the median of the age spectrum covered by UKB, and this repre-
sents approximately the turning point, when the association between 
DBP and age is reversed, due to increasing arterials stiffness.10,24 
Related individuals up to second-degree were excluded (relatedness 
coefficient <0.0884).25 We performed linear regression using age, sex, 
the first 20 principal components, genotyping chip, and assessment 
center as covariates.
Selection of Genetic Instruments
We identified genetic instruments for MAP and PP at age ≤55 and 
>55 years as single-nucleotide polymorphisms (SNPs) associated 
with MAP or PP at genome-wide significance level (P<5×10−8) and 
clumped based on the European 1000 Genomes panel to r2<0.01. 
We identified a total of 486 SNPs fulfilling these criteria, as detailed 
in Table I in the Data Supplement. We estimated the proportion of 
variance in MAP and PP in the 2 age groups explained by genetic 




The primary outcomes for our analyses were ischemic stroke and 
its Trial of Org 10172 in Acute Stroke Treatment-defined etiolog-
ical subtypes (large artery, cardioembolic, small vessel stroke), as 
well as ICH and its subtypes defined by hemorrhage location (deep 
and lobar). Genetic association estimates for ischemic stroke, and 
its subtypes were obtained from the MEGASTROKE multi-ethnic 
GWAS meta-analysis of 60 341 ischemic stroke cases (6688 large ar-
tery, 9006 cardioembolic, and 11 710 small vessel stroke cases) and 
454 450 controls.27 For ICH, we used summary statistics from the 
International Stroke Genetics Consortium GWAS meta-analysis in-
cluding 1545 cases (664 lobar, 881 deep) and 1481 controls.28
Validation Sample
MEGASTROKE and ISGC also include individuals with ischemic 
stroke or ICH occurring at ≤55 years of age (although they com-
prise in both data sets <10% of the samples). To validate the tem-
poral trends between genetically predicted blood pressure at age ≤55 
and >55 years with the risk of ischemic stroke and ICH, we further 
performed additional analyses in the UKB, restricted to incident first-
ever events (occurring after the baseline blood pressure measure-
ments) in individuals >55 years of age. These analyses included 3180 
incident ischemic stroke cases among 407 842 individuals and 655 
incident ICH events among 408 623 individuals. We explored the ge-
netic effects of the identified instruments using Cox regression analy-
ses to also consider in the analyses the time interval between blood 
pressure measurement and the occurrence of the incident events.
Statistics
Univariable Analyses
We first performed univariable MR analyses restricted to the instru-
ments specific for genetically predicted MAP and PP at age ≤55 or 
>55 years. The MR effect estimates were derived from multiplicative 
random-effects inverse-variance weighted MR analyses.29 Statistical 
significance was set at P<0.05. Because inverse-variance weighted 
is based on the assumption that the genetic instruments do not exert 
directional pleiotropy, to explore the robustness of our findings to 
the use of potentially pleiotropic variants, we further applied the 
weighted median estimator and the contamination mixture model. 
The weighted median estimator provides consistent estimates as long 
as at least half of the variants used in the MR analysis are valid.30 
The contamination mixture model constructs a likelihood function of 
the individual estimates and under the assumption that the estimates 
of the valid instruments would follow a distribution centered around 
the causal effect and any invalid instruments would follow a distribu-
tion around zero, it calculates MR estimates that would maximize this 
likelihood.31 The contamination mixture model assumes that some of 
the genetic variants used are valid instruments.31
Multivariable Analyses
Given the high genetic and phenotypic correlation between MAP 
and PP, we performed summary-data multivariable MR to dis-
entangle their independent associations with ischemic stroke, 
ICH, and their subtypes.32 Multivariable MR takes into account 
the effects of the genetic instruments on both exposure pheno-
types (MAP and PP) and thus allows us to disentangle the direct 
effects of the 2 phenotypes on the outcomes of interest, despite 
the presence of genetic overlap between them.32 For analyses for 
the effects of MAP and PP at age ≤55 years, we used 220 genetic 
variants associated with MAP or PP at P<5×10−8 in this age group, 
whereas for MAP and PP at age >55 years, we respectively used 
450 genetic variants associated with MAP or PP in this age group. 
Statistical significance was set at P<0.05. To deal with the imbal-
ance between the number of genetic instruments for MAP and PP, 
which could explain differences in the derived estimates, in sen-
sitivity analyses we randomly selected 100 SNPs associated with 
MAP plus 100 SNPs associated with PP in each age group and 
re-performed the multivariable analyses 1000 times.33
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Analyses Per Age Decile
To explore associations of genetically predicted MAP and PP across 
the entire age spectrum, we used all the 486 SNPs associated with 
MAP or PP at age ≤55 or >55 years and explored associations with 
MAP and PP across age deciles of the UKB at baseline. We then used 
these SNPs to perform multivariable MR analyses for the effects of 
both MAP and PP on risk of the examined outcomes at every decile. 
To explore trends of effect modification across the age spectrum, we 
then performed linear meta-regression analyses between the derived 
effect estimates for every decile and the respective median age per 
decile. Statistical significance was set at P<0.05.
Results
The baseline characteristics of individuals ≤55 or >55 years 
of age in the UKB are available in Table 2. A total of 486 
independent genetic variants were identified to be associated 
with MAP or PP at age ≤55 or >55 years (Table S1). Of those, 
133 and 100 variants were associated with MAP and PP at 
age ≤55 years and explained 3.6% and 1.6% of the variance, 
respectively. Furthermore, 197 and 249 variants were specifi-
cally associated with MAP and PP at age >55 years explaining 
3.3% and 5.7% of the variance, respectively. There was some 
overlap between the genetic variants associated with MAP 
and PP at age ≤55 and >55 years (Table S1). Specifically, 28 
of the 205 variants (14%) associated with MAP or PP at age 
≤55 years (P<5×10−8) showed significant associations with 
both phenotypes. In the older age stratum (>55 years), 47 of 
the 399 variants (12%) associated with MAP or PP showed 
significant associations with both phenotypes (Figure S1). In 
the univariable inverse-variance weighted MR analyses, we 
found both higher genetically predicted MAP and PP at both 
ages ≤55 and >55 years to be associated with higher risk of 
ischemic stroke (Table S2). Regarding ICH, we found sig-
nificant associations with higher genetically predicted MAP 
at age ≤55 and >55 years, as well as with higher genetically 
predicted PP at age >55 years. These results were stable in 
sensitivity alternative MR analyses (weighted-median, con-
tamination-mixture; Table S2).
To disentangle the independent effects of genetically 
predicted MAP and PP, we performed multivariable MR 
analyses. In the primary MEGASTROKE sample, higher ge-
netically predicted MAP at either ≤55 or >55 years of age was 
associated with higher risk of ischemic stroke independently 
of PP (odds ratio [OR] per 1 SD increment, 1.47 [95% CI, 
1.30–1.67] at ≤55 years; OR, 1.39 [1.26–1.53] at >55 years). 
On the contrary, only genetically predicted PP at age >55 
years showed an association with ischemic stroke beyond ge-
netically predicted MAP (OR, 1.11 [0.93–1.33] at ≤55 years; 
OR, 1.23 [1.13–1.34] at >55 years; Figure 1A). With regard to 
ICH, there were significant associations between higher ge-
netically predicted MAP at both ≤55 and >55 years of age 
with a higher risk (OR per 1 SD increment, 1.45 [95% CI, 
1.02–2.09] at ≤55 years; OR, 1.85 [1.23–2.77] at >55 years), 
whereas genetically predicted PP at either age stratum showed 
no significant independent association (Figure 1B). The 
results for both ischemic stroke and ICH were consistent in 
the validation sample of the UKB (sensitivity analysis), when 
restricting ischemic stroke cases to first-ever incident events 
occurring after 55 years of age (Figure 1). The results were 
also consistent in sensitivity analyses randomly selecting 100 
genetic variants associated with MAP and 100 variants asso-
ciated with PP for the young and the old age strata. This sen-
sitivity was done to account for the imbalance in the number 
of instruments and variance explained for MAP and PP across 
the age groups (Figure S2).
To explore the modifying effects of age on the associa-
tions between genetically predicted MAP and PP on risk of 
ischemic stroke and ICH across the entire age spectrum of 
the UKB population, we next explored associations across age 
deciles (Figure 2 and Table S3). Genetically predicted MAP 
was significantly associated with the risk of ischemic stroke 
across all age deciles, but there was a trend for an attenua-
tion of the effect with increasing age (P=0.02; Figure 2A). We 
found no significant effect of age on the associations between 
genetically predicted PP and risk of ischemic stroke (P=0.22), 
but there was a significant association only in the higher 
deciles (Figure 2A). No significant effects of age were identi-
fied on the associations of either genetically predicted MAP 
or PP with the risk of ICH, with higher genetically predicted 
Table 1. Data Sources That Were Used in the Analyses for the Current Mendelian Randomization Study
Phenotype Source N (Total or Cases/Controls)
Mean arterial and pulse pressure ≤55 y UK Biobank23,49 162 967 individuals
Mean arterial and pulse pressure >55 y UK Biobank23,49 245 261 individuals
Mean arterial and pulse pressure per age decile UK Biobank23,49 40 823 individuals
Ischemic stroke: primary sample MEGASTROKE27,50 60 341 cases, 454 450 controls
Incident ischemic stroke >55 y of age: validation sample UK Biobank49 3180 cases in 407 842 individuals
Large artery stroke MEGASTROKE50 6688 cases, 454 450 controls
Cardioembolic stroke MEGASTROKE50 9006 cases, 454 450 controls
Small vessel stroke MEGASTROKE50 11 710 cases, 454 450 controls
ICH: primary sample ISGC28 1545 cases, 1481 controls
Incident ICH >55 y of age: validation sample UK Biobank49 655 cases in 408 623 individuals
Deep ICH ISGC28 664 cases, 1481 controls
Lobar ICH ISGC28 881 cases, 1481 controls
ICH indicates intracerebral hemorrhage.
956  Hypertension  September 2020
MAP showing relatively consistent associations with higher 
risk across all age deciles, and genetically predicted PP show-
ing no significant association (Figure 2B). These results were 
consistent when repeating the analyses in the UKB validation 
sample (sensitivity analysis, Figure S3).
Next, we examined the effects of genetically predicted 
MAP and PP across the age deciles on ischemic stroke sub-
types in MEGASTROKE and on location-specific ICH in 
ISGC. For large artery stroke, we found a significant attenu-
ation of the effect of higher genetically predicted MAP with 
increasing age (P=0.003), as opposed to a gradually increas-
ing effect of genetically predicted PP (P=0.02; Figure 3). For 
cardioembolic stroke, we identified no significant trends with 
increasing age, but only higher genetically predicted PP at 
older age deciles showed significant associations with higher 
risk while the opposite seemed true for MAP. For small ves-
sel stroke, there was a uniform effect of higher genetically 
predicted MAP, but not PP, on higher risk across the entire age 
spectrum (Figure 3). For deep and lobar ICH, there were no 
trends for changing effects of genetically predicted MAP and 
PP across age (Figure 4). There were significant associations 
between higher genetically predicted MAP and higher risk 
of deep ICH, which seemed relatively consistent across age 
deciles. In contrast, there was no evidence of an association 
between either genetically predicted MAP or PP with lobar 
ICH at any age decile (Figure 4). Similar results were obtained 
in the dichotomous analyses for genetically predicted MAP 
and PP at age ≤55 and >55 years (Figure S4 and S5, Table S2).
Discussion
In the current study, we employed MR to explore the inde-
pendent effects of MAP and PP at different ages on risk of 
stroke. While genetically predicted MAP was associated with 
the risk of both ischemic and hemorrhagic across the entire 
examined age spectrum (38–71 years) independent of PP, its 
effect on ischemic stroke was attenuated with increasing age. 
Figure 1. Associations of genetically 
predicted mean arterial pressure (MAP) 
and pulse pressure (PP) at age ≤55 and 
>55 y with risk of (A) ischemic stroke and 
(B) intracerebral hemorrhage. Effect sizes 
are derived from multivariable Mendelian 
randomization analyses adjusting for 
both genetically predicted MAP and PP in 
MEGASTROKE (primary sample, 60 341 
cases, 454 450 controls) and the UK Biobank 
(validation sample, 3760 cases among 408 623 
individuals). The analysis of the UK Biobank 
is based on incident events that occurred 
in individuals >55 y of age after the blood 
pressure measurements.
Table 2. Baseline Characteristics of Participants in the UK Biobank Stratified by Age (≤55 y and >55 y)
Variables ≤55 Years, N=163 147 >55 Years, N=245 749
Age, y, mean (SD) 48.5 (4.4) 62.5 (3.8)
Sex, N (%)
  Male 72 657 (44.5) 115 229 (46.9)
  Female 90 490 (55.5) 130 520 (53.1)
SBP, mm Hg, mean (SD) 132.0 (16.7) 142.6 (18.7)
DBP, mm Hg, mean (SD) 81.9 (10.3) 82.6 (9.9)
MAP, mm Hg, mean (SD) 98.6 (11.8) 102.6 (11.8)
PP, mm Hg (SD) 50.1 (10.5) 60.0 (14.2)
BMI, kg/m2, mean (SD) 27.2 (5.0) 27.6 (4.6)
Current smokers, N (%) 20 440 (12.5) 20 880 (8.5)
Antihypertensive medication, N (%) 15 336 (9.4) 70 038 (28.5)
Diabetes mellitus, N (%) 4680 (2.9) 15 093 (6.2)
LDL cholesterol, mmol/L, mean (SD) 3.5 (0.8) 3.6 (0.9)
Statin use, N (%) 10 873 (6.7) 60 569 (24.6)
BMI indicates body mass index; DBP, diastolic blood pressure; LDL, low-density lipoprotein; MAP, mean arterial pressure; PP, pulse pressure; and SBP, systolic blood 
pressure.
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On the contrary, genetically predicted PP showed an effect 
on ischemic stroke independent of MAP only at older ages. 
Across subtypes, this differential effect was mostly prominent 
for large artery stroke, for which we found genetically pre-
dicted MAP at younger age (≤55 years) and genetically pre-
dicted PP at older age (>55 years) to be associated with higher 
risk. Collectively, our findings highlight a causal role of late-
life blood pressure pulsatility in ischemic stroke, in particular 
large artery stroke, on top of mean blood pressure.
It is still debated whether PP adds to cardiovascular risk 
stratification beyond SBP, DBP, and MAP.34 Current hyper-
tension guidelines focus on SBP and DBP and do not typi-
cally consider PP,35 although the European guidelines, based 
on large-scale observational studies,36,37 acknowledge that a 
PP >60 mm Hg in older hypertensive individuals increases 
cardiovascular risk.38 Using MR, the current study extends 
previous evidence by supporting that widened PP in later life 
represents an additional causal risk factor for ischemic stroke 
on top of the well-established effects of mean blood pressure. 
Given the differential effects of antihypertensive drug classes 
on PP,19,20,39 our findings could have clinical implications for 
the optimal management of elevated blood pressure in later 
life. Indeed, our findings suggest that future clinical trials 
exploring the efficacy of blood pressure-lowering approaches 
for stroke prevention should also consider changes in PP. In 
addition, novel approaches specifically aiming at decreasing 
pulsatility in later life could offer benefit on top of current 
blood pressure-lowering strategies.
We found the effect of late-life PP to be particularly strong 
for large artery atherosclerotic stroke. This is in agreement 
with existing evidence suggesting an unfavorable effect of 
widened PP on atherogenesis, atheroprogression, and plaque 
instability.40,41 Interestingly, we found this effect to be aug-
mented with increasing age, as opposed to an attenuating 
effect of increasing MAP. The precise mechanism of this find-
ing remains unknown, but we assume the observed pattern 
to be the result of increasing arterial stiffness with age.10,42 
Specifically, after an age of 50 to 60 years, the extracellular 
matrix of the arterial wall becomes less elastic, thus leading 
to decreased arterial compliance and increasing pulsatility.42,43
We found no evidence for an effect of genetically pre-
dicted PP at any age on risk of small vessel stroke or deep 
ICH, both of which are manifestations of cerebral small vessel 
disease.44 Previous observational studies on PP and neuroim-
aging markers of cerebral small vessel disease have provided 
inconsistent results.45 However, these results primarily orig-
inate from cross-sectional analyses of relatively small retro-
spective studies45 that are prone to confounding and reverse 
causation. On the contrary, we found the main determinant of 
both small vessel stroke and deep ICH throughout the exam-
ined age span to be MAP, in accord with the key role of el-
evated blood pressure on cerebral small vessel disease.44 Of 
note, we found no evidence for an association between either 
genetically predicted MAP or PP and lobar ICH. Unlike deep 
ICH, lobar ICH is related to cerebral amyloid angiopathy and 
the absence of an association signal between blood pressure 
and lobar ICH is consistent with observational46 and genetic7 
data.
To our knowledge, our study represents the first attempt 
to employ MR for the exploration of temporal trends across 
the lifespan in the associations between a risk factor and an 
outcome. Traditional MR examines genetic predisposition to 
a phenotype at any timepoint and may be interpreted as the 
effects of lifelong exposure to this phenotype on the outcome 
Figure 2. Associations of genetically 
predicted mean arterial pressure (MAP) 
and pulse pressure (PP) across age deciles 
with risk of (A) ischemic stroke and (B) 
intracerebral hemorrhage. Effect sizes 
are derived from multivariable Mendelian 
randomization analyses adjusting for both 
genetically predicted MAP and PP in every 
decile. The analyses are based on the 
MEGASTROKE sample for ischemic stroke 
and on the ISGC sample for intracerebral 
hemorrhage. Trends across age were explored 
with linear meta-regression analyses. OR 
indicates odds ratio.
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of interest.47 By exploiting data from the UKB, we were 
sufficiently powered to explore the independent effects of 
genetically predicted MAP and PP on risk of stroke and its eti-
ological subtypes across age deciles. We believe this approach 
could inform the design of future clinical trials including the 
optimal age group and the development of strategies for per-
sonalized medicine.
Our study also has limitations. First, the 2-sample MR 
setting might not be ideal for exploring temporal trends. For 
example, we cannot exclude that some of the stroke cases 
included in the outcome samples occurred at ages younger 
than the ages at which we examined the genetic deter-
minants of blood pressure. Yet, most of the stroke cases in 
MEGASTROKE and ISGC occurred long after the cutoff of 
55 years (mean age of cases 68.2 and 69.9 years, respectively), 
and our results were remarkably consistent in sensitivity anal-
yses including only first-ever incident cases >55 years of age 
in the UKB that occurred after the baseline blood pressure 
measurements. However, this sensitivity analysis could not 
be done for the stroke subtypes, as information on subtypes 
was not available in the UKB. Second, the different genetic 
determinants of blood pressure across the examined age 
groups might in part reflect a higher probability of older indi-
viduals to receive antihypertensive medications. To account 
for this, we adjusted for the effects of antihypertensive med-
ication in the original GWASs. Still, we cannot exclude a re-
sidual bias of this type on our findings. Third, as opposed to 
MAP, the variance explained by the genetic variants for PP 
was substantially lower at age ≤55 years as compared with 
>55 years. While this could have resulted in insufficient power 
to detect significant associations between PP at younger ages 
with the risk of stroke, this would be unlikely to explain the 
trend of the increasing association with large artery stroke 
in higher age deciles. Similarly, this would also be unlikely 
to result in the observed consistency of results in sensitivity 
analyses addressing the imbalance in the number of genetic 
instruments for the different phenotypes. Fourth, our analyses 
are based on brachial MAP and PP that were available in the 
UKB, which are less powerful predictors of future cardiovas-
cular events as central measurements.48 Similarly, there were 
no 24-hour ambulatory blood pressure measurements in the 
UKB, which comprise the gold standard method of assessing 
Figure 3. Associations of genetically 
predicted mean arterial pressure (MAP) 
and pulse pressure (PP) across age 
deciles with risk of ischemic stroke 
etiological subtypes—(A) large artery 
stroke, (B) cardioembolic stroke, (C) small 
vessel stroke. Effect sizes are derived from 
multivariable Mendelian randomization analyses 
adjusting for both genetically predicted MAP 
and PP in every decile. The analyses are based 
on the MEGASTROKE sample. Trends across 
age were explored with linear meta-regression 
analyses. OR indicates odds ratio.
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blood pressure. Fifth, despite using the largest currently avail-
able GWAS data sets, our analyses for some of the stroke sub-
types, especially for lobar and deep ICH subtypes may still 
have been underpowered. Finally, our analyses were primarily 
based on data sets involving individuals of European ancestry 
and might thus not be applicable to other ethnicities.
Perspectives
Our study supports distinct effects of genetically predicted MAP 
and PP across the lifespan on stroke risk. While MAP seems to 
have a causal effect on both ischemic and hemorrhagic stroke 
across the entire age spectrum, we provide evidence for an ad-
ditional independent effect of increasing PP at older ages on 
ischemic stroke, particularly large artery stroke. Our results 
complement findings from observational studies and warrant 
further investigation for the development of potential stroke pre-
ventive strategies targeting blood pressure pulsatility in later life.
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What Is New?
•	 This is the first Mendelian randomization study exploring the independent 
causal effects of mean arterial pressure and pulse pressure on risk of stroke.
•	This study further explores the differential effects of mean arterial pres-
sure and pulse pressure across different age strata on risk of stroke and 
its subtypes.
What Is Relevant?
•	On top of the well-established effect of mean arterial pressure across 
the entire age spectrum on risk of ischemic and hemorrhagic stroke, 
this study provides evidence for an independent effect of genetically pre-
dicted pulse pressure in later life on risk of ischemic stroke.
Summary
These findings provide evidence for a causal effect of late life blood 
pressure pulsatility on risk of ischemic stroke. Our results com-
plement previous findings from observational studies and warrant 
further investigation for the development of potential stroke pre-
ventive strategies targeting blood pressure pulsatility in later life.
Novelty and Significance
